Parmax Pharma Limited reported audited standalone earnings results for the fourth quarter and year ended March 31, 2018. For the quarter, the company reported revenue from operations was INR 315,920,065. Profit from operations before exceptional items and tax was INR 2,839,800 against INR 34,556 a year ago. Profit before tax was INR 2,839,800 against INR 34,556 a year ago. Profit for the period from continuing operations was INR 2,839,800 against INR 34,556 a year ago. Profit for the period was INR 2,839,800 or INR 0.76 basic and diluted per share against INR 34,556 or INR 0.01 basic and diluted per share a year ago. For the year, the company reported revenue from operations was INR 119,015,986. Profit from operations before exceptional items and tax was INR 16,542 against INR 51,213 a year ago. Profit before tax was INR 16,542 against INR 51,213 a year ago. Profit for the period from continuing operations was INR 16,542 against loss for the period from continuing operations of INR 78,787 a year ago. Profit for the period was INR 16,542 or INR 0.00 basic and diluted per share against loss for the period of INR 78,787 or INR 0.02 basic and diluted per share a year ago.